Heidi Altmann
A5004451037- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immune cells in cancer
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Histone Deacetylase Inhibitors Research
- Liver Disease Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Retinoids in leukemia and cellular processes
- Lymphoma Diagnosis and Treatment
- COVID-19 Clinical Research Studies
- Genomics, phytochemicals, and oxidative stress
- T-cell and B-cell Immunology
- Cancer Immunotherapy and Biomarkers
- Cytokine Signaling Pathways and Interactions
- COVID-19 and Mental Health
- Cancer-related gene regulation
- Alcohol Consumption and Health Effects
- Long-Term Effects of COVID-19
- Nanowire Synthesis and Applications
University Hospital Carl Gustav Carus
2017-2025
National Center for Tumor Diseases
2021-2025
Technische Universität Dresden
2017-2025
Friedrich Schiller University Jena
2024
Jena University Hospital
2024
Klinik und Poliklinik für Psychotherapie und Psychosomatik
2017-2024
German Cancer Research Center
2021-2023
Heidelberg University
2021-2023
Hopp Children's Cancer Center Heidelberg
2023
Helmholtz-Zentrum Dresden-Rossendorf
2023
Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological malignancy. Although immunotherapy may be an attractive modality to exploit in patients with AML, the ability predict groups of types cancer that will respond immune targeting remains limited. This study dissected complexity architecture AML at high resolution assessed its influence on therapeutic response. Using 442 primary bone marrow samples from three independent cohorts children adults we defined...
Abstract The major cause of death after allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for acute myeloid leukemia (AML) is disease relapse. We investigated the expression Inhibitory Receptors (IR; PD-1/CTLA-4/TIM-3/LAG-3/2B4/KLRG1/GITR) on T cells infiltrating bone marrow (BM) 32 AML patients relapsing (median 251 days) or maintaining complete remission (CR; median 1 year) HSCT. A higher proportion early-differentiated Memory (T SCM ) and Central BM-T express multiple IR in than...
Abstract Somatic TP53 mutations and 17p deletions with genomic loss of occur in 37% to 46% acute myeloid leukemia (AML) adverse-risk cytogenetics correlate primary induction failure, high risk relapse, dismal prognosis. Herein, we aimed characterize the immune landscape TP53-mutated AML determine whether abnormalities identify a patient subgroup that may benefit from immunotherapy flotetuzumab, an investigational CD123 × CD3 bispecific dual-affinity retargeting antibody (DART) molecule. The...
Background. Immune exhaustion and senescence are dominant dysfunctional states of effector T cells major hurdles for the success cancer immunotherapy. In current study, we characterized how acute myeloid leukemia (AML) promotes generation senescent-like CD8+ whether they have prognostic relevance.
Abstract Acute myeloid leukemia (AML) is a genetically heterogeneous hematological malignancy with variable responses to chemotherapy. Although recurring cytogenetic abnormalities and gene mutations are important predictors of outcome, 50% 70% AMLs harbor normal or risk-indeterminate karyotypes. Therefore, identifying more effective biomarkers predictive treatment success failure essential for informing tailored therapeutic decisions. We applied an artificial neural network (ANN)–based...
Abstract Purpose The objective examination of the Post-COVID syndrome (PCS) remains difficult due to heterogeneous definitions and clinical phenotypes. aim study was verify functionality correlates a recently developed PCS score. Methods score applied prospective, multi-center cross-sectoral cohort (in- outpatients with SARS-CoV-2 infection) "National Pandemic Cohort Network (NAPKON, Germany)". Symptom assessment patient-reported outcome measure questionnaires were analyzed at 3 12 months...
Abstract Ex vivo drug response profiling is a powerful tool to study genotype–drug associations and being explored as set for precision medicine in cancer. Here we conducted prospective non-interventional trial investigate feasibility of ex treatment guidance hematologic malignancies (SMARTrial, NCT03488641 ). The primary endpoint provide reports within 7 d was met 91% all participants ( N = 80). Secondary analysis revealed that resistance chemotherapeutic drugs predicted chemotherapy...
Clinical translation of novel immunotherapeutic strategies such as chimeric antigen receptor (CAR) T-cells in acute myeloid leukemia (AML) is still at an early stage. Major challenges include immune escape and disease relapse demanding for further improvements CAR design. To overcome hurdles, we have invented the switchable, flexible programmable adaptor Reverse (Rev) platform. This consists engineered with RevCARs that are primarily inactive they express extracellular short peptide epitope...
The quality of biological samples used in metabolomics research is significantly influenced by preanalytical factors, such as the timing centrifugation and freezing. This study aimed to evaluate how like delays freezing, affect research. Blood samples, collected various tube types, were subjected controlled pre- postcentrifugation delays. Metabolite levels quantified using NMR spectroscopy fitted linear mixed models predict changes metabolite concentrations over time. results showed that...
Adaptor chimeric antigen receptor (CAR) T-cell therapy offers solutions for improved safety and escape, which represent main obstacles the clinical translation of CAR in myeloid malignancies. The adaptor platform 'UniCAR' is currently under early investigation. Recently, first proof concept a well-tolerated, rapidly switchable, CD123-directed UniCAR product treating patients with acute leukaemia (AML) was reported. Relapsed refractory AML prone to high plasticity pressure targeting one...
Abstract Resistant disease is still a main obstacle in acute myeloid leukemia (AML) treatment. Therefore, individual genetic variations affecting therapy response are gaining increasing importance. Both SNPs and ABC transporter genes could already be associated with drug resistance. Here, we report allelic variants of MRP1 ( ABCC1 ) rs129081, rs212090, rs212091 significant influences on survival AML patients. DNA was extracted from bone marrow samples n = 160) at diagnosis. Genotyping 48...
We performed a registry-based analysis of 311 AML patients treated with decitabine in standard care setting to assess response and survival data distinct focus on the impact TP53 mutation status. Median age was 73 years. 172 received first-line 139 r/r disease. The ORR (whole cohort) 30% median overall 4.7 months. First-line achieved better responses than r/r-patients (ORR: 38% vs. 21%) resulting OS 5.8 months 3.9 NGS based 180 patients. 20 (11%) harbored mutation. Response rates did not...
We aimed to assess symptoms in patients after SARS-CoV-2 infection and identify factors predicting prolonged time symptom-free.COVIDOM/NAPKON-POP is a population-based prospective cohort of adults whose first on-site visits were scheduled ≥ 6 months positive PCR test. Retrospective data including self-reported symptom-free collected during the survey before site visit. In survival analyses, being served as event be variable. Data visualized with Kaplan-Meier curves, differences tested...
Summary Combinatory therapeutic approaches of different targeted therapies in acute myeloid leukaemia are currently under preclinical/early clinical investigation. To enhance anti‐tumour effects, we combined the tyrosine kinase inhibitor ( TKI ) midostaurin and T‐cell mediated immunotherapy directed against CD 33. Clinically relevant concentrations abrogated cytotoxicity both after activation with bispecific antibodies chimeric antigen receptor T cells. This information is relevance for...
Abstract Infectious events, such as sepsis and invasive fungal disease (IFD), pose significant risks in patients with acute myeloid leukemia (AML). Previous studies, including our own, have suggested a potential role of single nucleotide polymorphisms (SNPs) within the innate immune system influencing individual infection susceptibility. However, many these associations lack validation independent cohorts. This study sought to validate impact 11 candidate SNPs across 6 genes ( TLR2, TLR4,...
50 Background: Tumor phenotypes are dictated not only by the neoplastic cell component, but also tumor microenvironment (TME), which includes immune and inflammatory cells. We characterized ecosystem of bone marrow (BM) TME in patients with acute myeloid leukemia (AML) to correlate transcriptomic proteomic profiles patient outcome. Methods: used nCounter system (NanoString Technologies) characterize BM specimens from 42 children 28 adults AML. Ninety samples (63 de novo AML, 18 AML complete...
Abstract This study dissected the complexity of immune architecture acute myeloid leukemia (AML) at high resolution and assessed its influence on therapeutic response. Using 387 primary bone marrow samples from three discovery cohorts children adults with AML, we defined immune-infiltrated immune-depleted disease subtypes unraveled critical differences in gene expression across age groups stages. Importantly, interferon (IFN)-γ-related mRNA profiles were predictive for both chemotherapy...
Abstract Background Lysyl oxidase (LOX) has been described as necessary for premetastatic niche formation in epithelium-derived malignancies and its expression level therefore correlates with risk of metastatic disease overall survival. However, role acute myeloid leukemia (AML) not sufficiently analyzed. Methods We investigated LOX plasma 683 AML patients (age 17–60 years) treated within the prospective AML2003 trial (NCT00180102). The optimal cut-off value was determined using a minimal- p...
Precision medicine can significantly improve outcomes for patients with cancer, but implementation requires comprehensive characterization of tumor cells to identify therapeutically exploitable vulnerabilities. Here, we describe somatic biallelic TET2 mutations in an elderly patient acute myeloid leukemia (AML) that was chemoresistant anthracycline and cytarabine acutely sensitive 5'-azacitidine (5'-Aza) hypomethylating monotherapy, resulting long-term morphological remission. Given the role...
Abstract Growth factor independence 1 (GFI1) is a DNA-binding transcription and key regulator of hematopoiesis. GFI1-36N germ line variant, causing change serine (S) to asparagine (N) at position 36. We previously reported that the allele has prevalence 10% 15% among patients with acute myeloid leukemia (AML) 5% 7% healthy Caucasians promotes development this disease. Using multiomics approach, we show here expression associated increased frequencies chromosomal aberrations, mutational...